The P-III (TENAYA) & (LUCERNE) studies evaluating Vabysmo vs aflibercept in 1329 patients with wet AMD
The results showed that 59% & 67% of Vabysmo patients achieved 4mos. in (TENAYA) & (LUCERNE) studies @2yrs.; improvement above 1yr. outcomes (45% & 46%)., 80% could be treated q3mos. or longer at the end of 2yr., patients received a median number of 10 inj. vs 15 inj. @2yrs., reductions in CST in patients with Vabysmo given at ~4mos. vs aflibercept at q2mos. with no new safety signals, was well tolerated with a favorable benefit-risk profile
Improvements in vision across both treatment arms. The safety results were consistent with no reported cases of retinal vasculitis or IOI associated with retinal vein or retinal artery occlusion
Ref: Bussinesswire | Image: Genentech
